A research-use disclaimer is one part of a website, not a substitute for reading what the website actually offers. FDA’s August 24 letters to NuScience Peptides and Royal Peptides make that distinction tangible for a practitioner-facing directory: a molecule name, a branded approved medicine and a research seller’s product cannot share one regulatory-status badge.
What the two records establish
The NuScience letter describes a July website review and names nine products it regards as unapproved new drugs, including GLP-related products, PT-141, tesamorelin, a tesamorelin–ipamorelin blend and bacteriostatic water. Its footnote explicitly addresses wording that products are for laboratory, research and analytical use and not intended for human or veterinary use. FDA says the website evidence establishes human drug intended use despite those statements.
The letter also cites bacteriostatic water sold alongside a peptide calculator as evidence of means to prepare an injectable drug for human administration. That is FDA’s reasoning about this offer. It is not a claim that every calculator, research product or mention of the same molecule has an identical legal status.
The Royal letter names seven offered products, including retatrutide, SS-31, PT-141, tesamorelin and a tesamorelin–ipamorelin blend called BIMORELIN. FDA says no approved applications are in effect for the products named in the letter. Seven and nine are counts of named products in these specific records, not counts of unique peptide molecules or the size of an industry.
Preserve the product boundary
A statement about these sellers’ preparations must not become “FDA has never approved any product containing this molecule.” Conversely, the existence of an approved medicine containing a molecule would not validate another seller’s vial, blend or claims. In directory research, the identity of the product and the legal entity offering it matter as much as the molecule field.
The same discipline applies to the website claims quoted in a letter. They are evidence of what FDA reviewed and alleged—not endorsements of the medical benefits described. Quoting a seller’s visceral-fat, cognition or bone claims without that attribution would accidentally amplify the marketing under an official-looking citation.
A letter is a dated enforcement stage
These letters are administrative correspondence expressing FDA’s findings and requiring a response. They are not court judgments. This review did not verify a later company response, closeout, product withdrawal or current operating status. No inference of either remediation or continuing noncompliance follows from that gap. The August 24 issue date also differs from the September 1 content date shown on the Royal FDA page.
For a practice, the useful implication is documentary rather than a shopping recommendation: retain the exact seller, product identity, intended use and source date when assessing a supplier or communications claim. A directory should link the record and its unresolved follow-up state, not translate a warning letter into an automatic quality ranking. This research does not recommend research-use products for human care.
Evidence record
Event date: 2026-08-24. Source review: 2026-10-29. Editorial publication: 2026-10-29. Original source links below retain their publication dates. These dates are not interchangeable. This is targeted source synthesis, not an exhaustive archive or a qualified clinical/legal review.
- FDA NuScience letter 733652; August 24, 2026, including footnote 1 ↗
- FDA Royal letter 734884; August 24, 2026 ↗
Revision history
29 October 2026: expanded against the specifically cited source passages. Source review is not qualified clinical or legal review. Report a proposed correction through Contact us; do not include patient data.